Wilson S, Song W, Karoly K, Ravingerova T, Vegh A, Papp J, Tomisawa S, Parratt J R, Pyne N J
Department of Physiology and Pharmacology, University of Strathclyde, Glasgow, Scotland.
Mol Cell Biochem. 1996 Jul-Aug;160-161:225-30. doi: 10.1007/BF00240053.
Both noradrenaline administration to rats and rapid cardiac pacing in dogs induces delayed protection of the heart against ischaemia-induced ventricular arrhythmias. In an attempt to establish molecular mechanisms underlying the delayed cardioprotection, we have examined the potential role of two kinases, PKC epsilon and p42/44MAPK. These protein kinases are expressed in the ventricles of the heart and are characterised by their ability to regulate ion-flux and gene transcription. In the rat p42MAPK is predominantly localised in the high-speed supernatant fraction of the ventricle homogenate, whereas p44MAPK is enriched in the nuclear low speed pellet. A small proportion of the p42MAPK is activated even in hearts from control animals. However, neither kinase is relocalised or activated by noradrenaline administration and this provides preliminary evidence the p42/44MAPK may not play a significant role in delayed protection in this species. In contrast, noradrenaline does induce the translocation of PKC epsilon to cell membranes, a response that is sustained for up to 4 h. However, PKC epsilon is down-regulated from the cytoplasm after 24 h post noradrenaline treatment. PKC epsilon is also translocated to the membrane in dogs that have been classically pre-conditioned and cardiac paced. In the latter case, translocation of PKC epsilon from the cytoplasm to the cell membrane is evident 24 h after pacing. These results indicate that the release of endogenous mediators may either inhibit down-regulation or elicit an increase in PKC epsilon mRNA expression. Therefore, in dog heart the subcellular relocalisation of PKC epsilon persists into the 'second window' and may play a central role in the molecular mechanism governing delayed cardioprotection. It is important in the future to identify either the gene products that are induced or the target protein(s) that are phosphorylated by PKC epsilon.
给大鼠注射去甲肾上腺素以及对犬进行快速心脏起搏,均可诱导心脏产生延迟性保护作用,使其免受缺血性室性心律失常的影响。为了探究延迟性心脏保护作用背后的分子机制,我们研究了两种激酶——蛋白激酶Cε(PKCε)和p42/44丝裂原活化蛋白激酶(p42/44MAPK)的潜在作用。这些蛋白激酶在心室中表达,其特点是能够调节离子通量和基因转录。在大鼠中,p42MAPK主要定位于心室匀浆的高速上清组分中,而p44MAPK则富集于核低速沉淀中。即使在对照动物的心脏中,也有一小部分p42MAPK被激活。然而,给予去甲肾上腺素后,这两种激酶均未发生重新定位或激活,这初步证明p42/44MAPK在该物种的延迟性保护中可能不发挥重要作用。相比之下,去甲肾上腺素确实会诱导PKCε转位至细胞膜,这种反应可持续长达4小时。然而,去甲肾上腺素处理24小时后,PKCε会从细胞质中下调。在经过经典预处理和心脏起搏的犬中,PKCε也会转位至细胞膜。在后一种情况下,起搏后24小时,PKCε从细胞质转位至细胞膜的现象明显。这些结果表明,内源性介质的释放可能会抑制下调或引发PKCε mRNA表达增加。因此,在犬心脏中,PKCε的亚细胞重新定位持续至“第二窗口”,并可能在延迟性心脏保护的分子机制中发挥核心作用。未来确定PKCε诱导的基因产物或磷酸化的靶蛋白非常重要。